|Day Low/High||128.77 / 137.74|
|52 Wk Low/High||22.17 / 202.73|
Can the biotech help the Russell 2000 break out?
As usual, we have some bears forecasting a market disaster, but overall, stocks are in good shape technically.
The news sent shares of the genome editing company skyward after the stock had been basing for months.
Buyers make or break companies with their voting or buying or betting. Somedays it's all that matters.
These ARK Funds family funds are focused on new opportunities and investment themes.
Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'
Not much movement in the markets so far today as the trading week begins. Major indices are in a narrow range and have fluctuated between slight losses and negligible gains throughout this morning. Tesla is off over 3% following up on some weakness...
The setup here is appealing enough to take a small, aggressive shot on the long side.
Oncology firm released results that show increased compliance with Optune predicted increased survival in patients with glioblastoma, a form of brain cancer.
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.